language_icon
EN
HI

Thyrocare Technologies Share price

THYROCARE

477.35

2.35 (0.49%)
NSE
BSE
Last updated on 13 May, 2026 | 15:53 IST
Today's High

493.55

Today's Low

471.00

52 Week Low

291.37

52 Week High

536.67

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Thyrocare Technologies Chart

Thyrocare Technologies Share Key Metrics

Volume
4.59 L
Market Cap
7597.76 CR
LTQ@LTP
196@477.35
ATP
483.54
Var Margin
19.79 %
Circuit Range
380-570
Delivery %
44.12 %
Value
22.20 CR
ASM/GSM
No
Market Lot
1

Summary

13 May, 2026 | 15:53 को, Thyrocare Technologies का शेयर प्राइस आज ₹477.35 पर है, जो दिन के लिए 2.35% की 0.49 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹471.00 और ₹493.55 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹291.37 से ₹536.67 तक रही है। ट्रेडिंग गतिविधि के मामले में, Thyrocare Technologies ने 459123 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹159165315 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹48354 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 196,47735 रही। यह स्टॉक ₹380-570 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹22.20 CR है। दिन के लिए डिलीवरी परसेंटेज 44.12% रही। इसके अतिरिक्त, Thyrocare Technologies वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Thyrocare Technologies Fundamentals

View More
P/E Ratio

46.43

P/B Ratio

12.93

Div. Yield

2.94

Sector P/E

55.61

Sector P/B

-15.8

Sec. Div. Yield

1.93

Thyrocare Technologies Resistance and Support

Pivot 474.07

Resistance

First Resistance

481.84

Second Resistance

488.67

Third Resistance

496.44

Support

First Support

467.24

Second Support

459.47

Third Support

452.64

Thyrocare Technologies Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

71.06%

Mutual Fund

12.75%

Insurance

1.06%

Foreign Institutional Investors

2.77%

Domestic Institutional Investors

0.86%

Retail

11.5%

Others

0%

Total Promoters
MAR '24
71.11%
JUN '24
71.11%
SEP '24
71.11%
DEC '24
71.06%

Thyrocare Technologies Corporate Actions

DateAgenda
2026-05-07Audited Results & Final Dividend
2026-01-28Quarterly Results

Thyrocare Technologies News

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Thyrocare Technologies announced the audio recording of its earnings conference call, held on May 12, 2026, for the quarter and financial year ended March 31, 2026, is now available on the company's website for investor access. The transcript will be shared shortly.
May 12 2026 14:05:00

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association

Thyrocare Technologies' Board approved altering its Memorandum of Association (MOA) to broaden the company's business scope within the healthcare and diagnostics ecosystem. This change, pending shareholder approval, enables the company to undertake a wider range of activities, including allied services and related products.
May 07 2026 19:05:00

Thyrocare Technologies Ltd - 539871 - Appointment Of Cost Auditors For The Financial Year 2026-27

Thyrocare's Board met on May 7, 2026, and recommended a final dividend of Rs. 7.00 per share for FY2025-26. The board also approved the appointment of new statutory and cost auditors, re-appointment of MD & CEO, and made changes to other directors.
May 07 2026 19:05:00

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

Thyrocare Technologies' board approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as statutory auditors for a five-year term. This appointment is subject to shareholder approval at the upcoming AGM.
May 07 2026 19:05:00

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Change in Directorate

Thyrocare Technologies re-appointed Mr. Rahul Franklin Guha as Chairman, Managing Director & CEO for a five-year term, effective May 4, 2027, subject to shareholder approval. This ensures continued leadership for strategic initiatives.
May 07 2026 19:05:00

Thyrocare Technologies Ltd - 539871 - Corporate Action-Board approves Dividend

Thyrocare board recommended a final dividend of ₹7.00 per equity share for FY26. Including the interim dividend, the total payout for the fiscal year amounts to ₹9.33 per share (post bonus adjustment).
May 07 2026 19:05:00

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Thyrocare Technologies announced robust Q4 FY26 consolidated results, with revenue growing 20% YoY to Rs.223.95 cr and net profit soaring 128% YoY to Rs.48.70 cr. The company also reported strong annual growth for FY26.
May 07 2026 18:05:00

Thyrocare Technologies Ltd - 539871 - Board Meeting Outcome for Outcome Of The Board Meeting Held On May 07, 2026

Thyrocare Technologies board approved its FY26 audited financial results and recommended a final dividend of ₹7.00 per equity share. The board also re-appointed Rahul Guha as CMD for five years and approved a ₹5.50 crore investment in its wholly-owned subsidiary, Think Health Diagnostics Private Limited.
May 07 2026 17:05:00

Thyrocare Technologies Ltd - 539871 - Cancellation Of Earning Conference Call

Thyrocare Technologies announced the cancellation of its earnings conference call for analysts/investors, which was scheduled for May 07, 2026. The call was intended to discuss the company's Audited Financial Results for Q4 and FY26. A revised schedule will be provided later.
May 07 2026 17:05:00

Thyrocare Technologies Ltd - 539871 - Corporate Action-Board to consider Dividend

Thyrocare Technologies board to meet on May 07, 2026, to consider a final dividend for FY 2025-26. This decision is crucial for shareholder returns.
Apr 29 2026 13:04:00
Read More

About Thyrocare Technologies AboutThe

NSE : 17032  
BSE : 539871  
ISIN : INE594H01019  

The Company was incorporated as Thyrocare Technologies Limited on January 28 2000 at Mumbai as a public limited company under the Companies Act 1956. the Company was issued a certificate of commencement of business from the RoC on March 7 2000. Major events and milestones of the Company :2000-The Company was incorporated in the name and style of "Thyrocare Technologies Limited? and received a certificate for commencement of operations. 2001-The Company received ISO 9001 certification. -The Company commenced commercial operations under the brand name 'Thyrocare' pursuant to the acquisition of business of TDPL and TBPL (which were incorporated in 1996). 2005-The Company received NABL accreditation. 2006-The Company issued certain fully convertible debentures aggregating to 250 million to BCCL. 2007-The Company receives accreditation from the College of American Pathologists (CAP). 2010-The Company issued certain compulsorily convertible debentures aggregating to 250 million to Agalia. Agalia also acquired certain Equity Shares aggregating to 1250 million from the Promoters and certain other persons. -The Company launched wellness packages under the brand name "Aarogyam". 2011-The Company migrated to "total laboratory automation system" installed by Siemens for efficient handling of increasing volumes. 2012-NVP acquired certain Equity Shares aggregating to 1200 million from certain entities. 2013-EIF acquired certain Equity Shares from Agalia. -The Subsidiary commenced operations at the PET-CT centres at Navi Mumbai and conducted over 1000 scans in the first year of operation. 2014-The Company had installed India?s first and the world?s longest track automation system for seamless sample movements from Siemens Limited. -The Company commissioned the operations in medical cyclotron facility in Navi Mumbai. -The Subsidiary commenced operations at the PET-CT centres in New Delhi and Hyderabad and the PET-CT centres at New Delhi conducted over 1000 scans in the first year of operations. 2015-The Company opened RPLs in Delhi Coimbatore Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily. -The Company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name "WHATERS". These tests at present include physical and chemical testing elements testing microbiology testing pesticide testing and volatile organic compounds testing. -The Subsidiary has completed over 10000 scans at the PET-CT centres in New Delhi over 10000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1000 scans at the PET-CT centres in Hyderabad since inception.

Read More

Thyrocare Technologies Management

NamePosition
Brijesh KumarCompany Secretary & Compliance Officer
Rahul GuhaManaging Director & Chief Executive Officer
View More

Thyrocare Technologies FAQs

Thyrocare Technologies शेयर का खरीद मूल्य 477.35 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Thyrocare Technologies शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Thyrocare Technologies शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 46.43 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Thyrocare Technologies शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 12.93 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Thyrocare Technologies शेयर का प्राइस-टू-बुक (पी/बी) रेशियो -15.8 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Thyrocare Technologies का मार्केट कैप 7597.76 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Thyrocare Technologies शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 536.67 और 291.37 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost